menu
    • menu

    Company profile for Rhythm Pharmaceuticals

    NEW Drugs in Dev: 6
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Rhythm is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company recently announced positive topline results from pivotal Phase 3 clinical trials of setmelanotide, its MC4R agonist, in people living with POMC deficiency obesity and LEPR deficiency obesity and plans to complete its first rolling NDA submission to th...
    Rhythm is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company recently announced positive topline results from pivotal Phase 3 clinical trials of setmelanotide, its MC4R agonist, in people living with POMC deficiency obesity and LEPR deficiency obesity and plans to complete its first rolling NDA submission to the FDA in the first quarter of 2020.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Rhythm PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Rhythm Pharmaceuticals, Inc. 222 Berkeley Street, 12th Floor Boston, MA 02116
    Telephone
    Telephone
    857-264-4280
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.rhythmtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/rhythm-pharmaceuticals-inc-
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/rhythmpharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rhythm Pharma Reveals 2025 Net Sales, Future Goals
    Rhythm Pharma Reveals 2025 Net Sales, Future Goals

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3216057/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2025-Net-Product-Revenues-and-Upcoming-Milestones.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share
    Rhythm Pharma's Setmelanotide Effective in Prader-Willi Syndrome
    Rhythm Pharma's Setmelanotide Effective in Prader-Willi Syndrome

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203809/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Data-from-Exploratory-Phase-2-Trial-that-showed-Setmelanotide-Demonstrated-Positive-Efficacy-Signal-in-Prader-Willi-Syndrome.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Rhythm Pharma: Setmelanotide Ph 2 Data in Prader-Willi Syndrome
    Rhythm Pharma: Setmelanotide Ph 2 Data in Prader-Willi Syndrome

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3203492/0/en/Rhythm-Pharmaceuticals-to-Announce-Preliminary-Data-from-Exploratory-Phase-2-Trial-Evaluating-Setmelanotide-in-Prader-Willi-Syndrome.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Rhythm Pharma Reveals Four Datasets At Obesityweek Conference
    Rhythm Pharma Reveals Four Datasets At Obesityweek Conference

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184364/0/en/Rhythm-Pharmaceuticals-Announces-Presentation-of-Four-Datasets-at-ObesityWeek-2025.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    FDA Extends Review For IMCIVREE In Acquired Hypothalamic Obesity
    FDA Extends Review For IMCIVREE In Acquired Hypothalamic Obesity

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183568/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Extension-of-Review-Period-for-IMCIVREE-setmelanotide-for-Patients-with-Acquired-Hypothalamic-Obesity.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Rhythm Pharma Launches IMCIVREE Reimbursement In Canada
    Rhythm Pharma Launches IMCIVREE Reimbursement In Canada

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181893/0/en/Rhythm-Pharmaceuticals-Announces-Public-Reimbursement-for-IMCIVREE-setmelanotide-in-Canada-in-Five-Provinces-and-Under-the-Federal-Non-Insured-Health-Benefits-Program.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

    Details:

    Bivamelagon is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hypothalamic Obesity.


    Lead Product(s): Bivamelagon

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 05, 2025

    blank

    01

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bivamelagon

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

    Details : Bivamelagon is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hypothalamic Obesity.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    September 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

    Details:

    The net procceds from the offering will be used for the commercialization activities for Imcivree (Setmelanotide Acetate). It is being indicated for the treatment of obesity.


    Lead Product(s): Setmelanotide Acetate

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Imcivree

    Study Phase: Approved FDFProduct Type: Peptide, Unconjugated

    Sponsor: Morgan Stanley

    Deal Size: $175.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering July 10, 2025

    blank

    02

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Setmelanotide Acetate

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Morgan Stanley

    Deal Size : $175.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

    Details : The net procceds from the offering will be used for the commercialization activities for Imcivree (Setmelanotide Acetate). It is being indicated for the treatment of obesity.

    Product Name : Imcivree

    Product Type : Peptide, Unconjugated

    Upfront Cash : Undisclosed

    July 10, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

    Details:

    The net procceds from the offering will be used for the commercialization activities for Imcivree (Setmelanotide Acetate). It is being indicated for the treatment of obesity.


    Lead Product(s): Setmelanotide Acetate

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Imcivree

    Study Phase: Approved FDFProduct Type: Peptide, Unconjugated

    Sponsor: Morgan Stanley

    Deal Size: $150.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering July 09, 2025

    blank

    03

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Setmelanotide Acetate

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Morgan Stanley

    Deal Size : $150.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

    Details : The net procceds from the offering will be used for the commercialization activities for Imcivree (Setmelanotide Acetate). It is being indicated for the treatment of obesity.

    Product Name : Imcivree

    Product Type : Peptide, Unconjugated

    Upfront Cash : Undisclosed

    July 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rhythm's Phase 3 Trial Hits Primary Goal in Hypothalamic Obesity

    Details:

    Imcivree (setmelanotide acetate) is a subcutaneously administered, MC4 R agonist. It is being investigated for the treatment of acquired hypothalamic obesity.


    Lead Product(s): Setmelanotide Acetate

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Imcivree

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 07, 2025

    blank

    04

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Setmelanotide Acetate

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rhythm's Phase 3 Trial Hits Primary Goal in Hypothalamic Obesity

    Details : Imcivree (setmelanotide acetate) is a subcutaneously administered, MC4 R agonist. It is being investigated for the treatment of acquired hypothalamic obesity.

    Product Name : Imcivree

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    April 07, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rhythm to Share Phase 3 Results of Setmelanotide for Obesity

    Details:

    Imcivree (setmelanotide) is a subcutaneously administered, MC4 R agonist. It is being investigated for the treatment of acquired hypothalamic obesity.


    Lead Product(s): Setmelanotide Acetate

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Imcivree

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 01, 2025

    blank

    05

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Setmelanotide Acetate

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rhythm to Share Phase 3 Results of Setmelanotide for Obesity

    Details : Imcivree (setmelanotide) is a subcutaneously administered, MC4 R agonist. It is being investigated for the treatment of acquired hypothalamic obesity.

    Product Name : Imcivree

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    April 01, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rhythm Reacquires IMCIVREE® China Rights with RareStone Agreement Termination

    Details:

    Through the termination, Rhythm will reacquires the rights of Imcivree (setmelanotide acetate). It is being indicated for the treatment of obesity.


    Lead Product(s): Setmelanotide Acetate

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Imcivree

    Study Phase: Approved FDFProduct Type: Peptide, Unconjugated

    Recipient: RareStone Group

    Deal Size: $6.3 million Upfront Cash: $6.3 million

    Deal Type: Termination March 20, 2025

    blank

    06

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Setmelanotide Acetate

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Approved FDF

    Recipient : RareStone Group

    Deal Size : $6.3 million

    Deal Type : Termination

    DEALS_DEV arrow-down

    Rhythm Reacquires IMCIVREE® China Rights with RareStone Agreement Termination

    Details : Through the termination, Rhythm will reacquires the rights of Imcivree (setmelanotide acetate). It is being indicated for the treatment of obesity.

    Product Name : Imcivree

    Product Type : Peptide, Unconjugated

    Upfront Cash : $6.3 million

    March 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rhythm Wins Orphan Drug Status for Setmelanotide in Japan

    Details:

    Imcivree (setmelanotide) is a subcutaneously administered, MC4 R agonist. It is being investigated for the treatment of acquired hypothalamic obesity.


    Lead Product(s): Setmelanotide Acetate

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Imcivree

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 19, 2025

    blank

    07

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Setmelanotide Acetate

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rhythm Wins Orphan Drug Status for Setmelanotide in Japan

    Details : Imcivree (setmelanotide) is a subcutaneously administered, MC4 R agonist. It is being investigated for the treatment of acquired hypothalamic obesity.

    Product Name : Imcivree

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    March 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Single-center Study of Setmelanotide in Patients With Prader-Willi Syndrome

    Details:

    Setmelanotide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prader-Willi Syndrome.


    Lead Product(s): Setmelanotide Acetate

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 13, 2025

    blank

    08

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Setmelanotide Acetate

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Single-center Study of Setmelanotide in Patients With Prader-Willi Syndrome

    Details : Setmelanotide is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prader-Willi Syndrome.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    January 13, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

    Details:

    Setmelanotide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypothalamic Obesity.


    Lead Product(s): Setmelanotide Acetate

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 07, 2025

    blank

    09

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Setmelanotide Acetate

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT0577475...

    Details : Setmelanotide is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypothalamic Obesity.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    January 07, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® for Children 2+

    Details:

    Imcivree (setmelanotide) is a MC4 R agonist. It is the approved weight management treatment in pediatric patients (2-6 years) with obesity due to Bardet-Biedl syndrome.


    Lead Product(s): Setmelanotide Acetate

    Therapeutic Area: Genetic Disease Brand Name: Imcivree

    Study Phase: Approved FDFProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 20, 2024

    blank

    10

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed

    Rhythm Pharmaceuticals

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Setmelanotide Acetate

    Therapeutic Area : Genetic Disease

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® for Children 2+

    Details : Imcivree (setmelanotide) is a MC4 R agonist. It is the approved weight management treatment in pediatric patients (2-6 years) with obesity due to Bardet-Biedl syndrome.

    Product Name : Imcivree

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    December 20, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search